Vaccine has been approved in China, Mexico, Pakistan, Hungary and Chile
Provides timely clinical protection for adults aged 18 and above, including those over 60
TIANJIN, China, May 24, 2021 /PRNewswire/ CanSino Biologics Inc. ( CanSinoBIO ) (SHSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™), has been granted a Good Manufacturing Practice ( GMP ) certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI). The certification was issued on May 21, 2021 after a thorough inspection of CanSinoBIO s production of Convidecia™.
The GMP certificate recognizes that CanSinoBIO s manufacturing facilities and quality control system comply with the high production standards and guidelines required by the European Union ( EU ). The EU GMP certification is required to import COVID-19 vaccines into the European Union and is regarded as a recognition of leading ind
Ankylosing Spondylitis Market Research Report by Drug, by Type of Molecule, by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 Ankylosing Spondylitis Market Research Report by Drug (Cimzia, Cosentyx, Enbrel, Humira, and Remicade), by Type of Molecule (Biologics and Small Molecules), by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
February 24, 2021 08:34 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, Feb. 24, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Ankylosing Spondylitis Market Research Report by Drug, by Type of Molecule, by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 - https://www.reportlinker
Shanghai launched 64 new projects with a combined investment of 273.4 billion yuan ($42.2 billion) on Monday, involving high-end industries, scientific and technological innovation, infrastructure, major livelihood and other fields.
The projects will spread across the city and will further unleash Shanghai s enormous development potential. It includes manufacturing, integrated circuits, biomedical and artificial intelligence projects, as well as high-end industrial chain programs of technological innovation, finance and trading.
Shanghai s economy has largely remained resilient despite the COVID-19 effect. From January to November, its fixed assets investment grew by 10.7 percent on a yearly basis, while manufacturing investment rose by 19.3 percent, the 33rd month in a row of double-digit growth.